Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Biocon | Adalimumab | Hulio |  | 2020-07-06 |  |  |
Johnson & Johnson | Infliximab | Remicade |  | 1998-08-24 | $1,552 M | Q4/23-Q3/24 |
Ustekinumab | Stelara |  | 2009-09-25 | $10,765 M | Q4/23-Q3/24 | |
Sandoz | Adalimumab | Halimatoz |  | 2018-07-26 |  |  |
Adalimumab | Hefiya |  | 2018-07-26 |  |  | |
Adalimumab | Hyrimoz |  | 2018-10-30 |  |  | |
Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol | Infuvite |  | 2000-05-18 |  |  | |
Infliximab | Zessly |  | 2018-05-18 |  |  | |
Natalizumab | Tyruko |  | 2023-08-24 |  |  | |
Methotrexate | Methotrexate |  | 2009-03-31 |  |  | |
Boehringer Ingelheim | Adalimumab | Cyltezo |  | 2017-08-25 |  |  |
Organon | Alendronate, Cholecalciferol | Fosamax D |  | 2005-04-07 |  |  |
AbbVie | Adalimumab | Humira |  | 2002-12-31 | $10,615 M | Q4/23-Q3/24 |
UCB | Certolizumab pegol | Cimzia |  | 2008-04-22 |  |  |
Pfizer | Adalimumab | Abrilada |  | 2019-11-15 |  |  |
Adalimumab | Amsparity |  | 2020-02-13 |  |  | |
Infliximab | Inflectra |  | 2013-09-10 | $490 M | Y2023 | |
Infliximab | Ixifi |  | 2017-12-13 |  |  | |
Takeda | Vedolizumab | Entyvio |  | 2014-05-20 |  |  |
Rising Pharmaceuticals | Azathioprine | Azathioprine |  | 1999-12-13 |  |  |
Methotrexate | Methotrexate |  | 2012-03-29 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|